ArticleMedicine2026
DOACs reduce risk for new-onset portal hypertension in patients with cirrhosis and atrial fibrillation: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with liver cirrhosis and atrial fibrillation (AF) pose a therapeutic challenge due to the conflicting risks of thrombosis and bleeding. The role of direct oral anticoagulants (DOACs) in this population remains uncertain. This study aims to evaluate the impact of anticoagulation therapy on new-onset portal hypertension and related complications in cirrhotic patients with AF. A retrospective cohort study was conducted in 502 hospitalized patients with cirrhosis and AF at Beijing Ditan Hospital (2010-2019). Clinical data, risk scores, and liver severity indices (Child-Pugh, Model for End-Stage Liver Disease) were collected. Propensity score matching was applied to minimize confounding. Primary endpoints were new-onset portal hypertension and all-cause mortality; secondary endpoints included gastrointestinal bleeding and thromboembolic events. Among 502 patients, 50 received oral anticoagulation. Anticoagulation was associated with a significantly lower risk of new-onset portal hypertension (P < .001) and gastrointestinal bleeding (P < .005) without increasing mortality (P < .003). After propensity score matching (n = 233), anticoagulation continued to reduce portal hypertension (P < .026) and gastrointestinal bleeding (P < .025), with no significant effect on mortality. Kaplan-Meier analysis confirmed improved survival in the anticoagulation group (P < .002). In cirrhotic patients with AF, anticoagulation, particularly direct oral anticoagulants, may lower the risk of portal hypertension and gastrointestinal bleeding without increasing mortality. Prospective studies are warranted to confirm these findings and guide clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.